[10 years of L-DOPA therapy of Parkinson's syndrome].
D000284:Administration, Oral; D000661:Amphetamine / Q000627:therapeutic use; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D002395:Catecholamines / Q000378:metabolism; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000139:chemically induced; D003248:Constipation / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004298:Dopamine / Q000032:analysis; D004357:Drug Synergism; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D006834:Hydrazines / Q000627:therapeutic use; D006973:Hypertension / Q000139:chemically induced; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009638:Norepinephrine / Q000032:analysis; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D012701:Serotonin / Q000032:analysis; D013268:Stimulation, Chemical; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D002395:Catecholamines; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D004295:Dihydroxyphenylalanine; D000661:Amphetamine; D004298:Dopamine; D009638:Norepinephrine
10 Jahre L-DOPA-Therapie des Parkinsonsyndroms.